AI Compassby Digital Pharma Lab
DEMO MODULE 04 · AI REGULATIONS

AI compliance monitoring dashboard

Back to productSee a use case in focus
AI Compass
Dashboard · Your laboratory
Updated 4 min agoMR
MODULE 04 · AI REGULATIONS

AI compliance overview

COMPLIANCE SCORE
72/100 +5
AI TOOLS MONITORED
17incl. 3 new
12 internal · 5 vendors
HIGH-RISK CASES
4non-compliant
Action required
NEXT DEADLINE
2 August 2026
AI Act art. 4 · D-71

Maturity by dimension

AI Governance84
Data & pharma quality68
Annex IV documentation42
Transparency (art. 50)79
Vendor due diligence65
AI Literacy (art. 4)91

AI tools deployed · use-case tracking

Copilot Microsoft 365
Productivity · cross-functional
Limited risk
88/100
Compliant
PV-Signal AI
Pharmacovigilance · signal detection
High risk
54/100
To monitor
DiagAssist (DM connecté)
Medical device · class IIa
High risk MDR
31/100
Non-compliant
MedWriter GPT
Medical writing · CSR reports
Limited risk
76/100
Compliant
MLR Co-Pilot
Marketing · material validation
Moderate risk
69/100
To monitor
Tip: click on 'Copilot Microsoft 365' to see a use case in focus →

Score trend · last 6 months

100602572Dec.Jan.Feb.Mar.Apr.May
Your score Pharma benchmark
DEMO MODULE 04 · TOOL DRILL-DOWN

Use case in focus — Copilot Microsoft 365

Back to dashboard
AI Compass
Dashboard · Your laboratory
Updated 4 min agoMR
OverviewAI tools deployedCopilot Microsoft 365

Copilot Microsoft 365

LIMITED RISK — AI ACT
Microsoft Corp. · 2,340 active users · Deployed since April 2024
COMPLIANCE SCORE
88/ 100 +3
TRACKED USE CASES
6out of 6 functions
TO MONITOR
2use cases
NON-COMPLIANT
1action required

Tracked use cases · regulatory risk level

Continuous compliance assessment against the AI Act, GDPR, EMA Reflection Paper and applicable pharma regulations.

SALES
COMPLIANT
Sales performance analysis

Assists with sales KPI analysis. No patient data, no HCP promotion generated.

AI Act risk: Minimal
MARKETING
TO MONITOR
MLR material generation

Production of HCP promotional content. Subject to EMA Reflection Paper LLM + MLR obligations.

AI Act risk: Limited — transparency
MEDICAL
COMPLIANT
Scientific literature synthesis

Publication summaries, MSL support. Internal use, human oversight in place.

AI Act risk: Limited
HR
COMPLIANT
Job postings & onboarding drafting

Excludes automated recruitment decisions. No candidate scoring.

AI Act risk: Minimal
FINANCE
COMPLIANT
Excel reporting analysis

Dashboard synthesis, anomaly detection. Internal financial data only.

AI Act risk: Minimal
CROSS-FUNC.
NON-COMPLIANT
Teams meeting summaries

Automatic transcription without participant notification. Potential medical data not encrypted.

AI Act risk: Limited — transparency art. 50
Use case in focus · MLR material generation
Marketing teams · limited risk · regulatory analysis
Compliance by framework
AI Act · art. 50 transparencyPartial
EMA Reflection Paper LLMGap
Pharma MLR codeCompliant
GDPR · HCP dataCompliant
AI Literacy art. 4Partial
Risk level trend · 6 months
HighModerateLowDec.Jan.Feb.Mar.Apr.MayEMA Q&A LLM

Risk increase driven by publication of the EMA LLM Q&A (March 2026) and the approaching AI Act art. 50 deadline.

Recommended actions to bring this use case into compliance

Document promotional use in accordance with the EMA LLM Q&A. Recommended deadline: before 30 June 2026.

Implement AI labelling on all generated content (watermark + visible notice) before 2 August 2026.

Complete AI Literacy training for the 386 marketing users — dedicated MLR materials module.

Preview · fictitious data.This screen illustrates the dashboard that the Watch module will deliver for a fictitious laboratory ('PharmaCorp'). No real data is used. The module is in development — pilot programme open.
WANT THIS DASHBOARD FOR YOUR TOOLS?

AI Regulations opens its pilot programme

Pilot rate −40%, 6-month early access, private product committee.

Become an AI Regulations pilot
Talk to a consultant